Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP-38 in recurrent glioblastoma multiforme
NCT00071539Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2003
- Primary completion
- Jan 2006
- Modality
- Recombinant Proteins and Enzymes, Immunotoxins
01
Overview
Phase 2, open-label trial of tp-38 in glioblastoma multiforme (GBM) (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Survival at 28 weeks. Started Oct 2003; status: completed.
02
Drugs
tp-38
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00071539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00071539.